REGENXBIOs Breakthrough in Duchenne Muscular Dystrophy Treatment
REGENXBIO Breakthrough in Duchenne Muscular Dystrophy Treatment REGENXBIO, a leader in gene therapy innovations, has achieved remarkable progress in the ...
Tag: RGNX
Analysts Upbeat on Regenxbios Future Prospects
Regenxbio's shares have surged following an upgrade from RBC Capital, who raised their price target to $35 and upgraded the ...
Wedbush Analyst Maintains Neutral Rating on Regenxbio with 21 Price Target
Wedbush analyst Andreas Argyrides has once again assessed Regenxbio (NASDAQ:RGNX) with a Neutral rating and upholds a $21 price target. ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
